scholarly journals Post Stroke Use of Selective Serotonin Reuptake Inhibitors and Clinical Outcome Among Patients With Ischemic Stroke

Stroke ◽  
2013 ◽  
Vol 44 (2) ◽  
pp. 420-426 ◽  
Author(s):  
Janne Kaergaard Mortensen ◽  
Heidi Larsson ◽  
Søren Paaske Johnsen ◽  
Grethe Andersen
Keyword(s):  
Ischemic Stroke ◽  
Clinical Outcome ◽  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Serotonin Reuptake Inhibitors ◽  
Selective Serotonin ◽  
Post Stroke

scholarly journals Post-stroke depression and the abilities of antidepressants to enhance the effectiveness of neurorehabilitation

2020 ◽  
Vol 12 (6) ◽  
pp. 110-116
Author(s):  
S. V. Kotov ◽  
E. V. Isakova ◽  
Yu. V. Egorova
Keyword(s):  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Recovery Period ◽  
Serotonin Reuptake Inhibitors ◽  
Selective Serotonin ◽  
Early Recovery ◽  
Post Stroke ◽  
Optimal Drug ◽  
Post Stroke Depression ◽  
Early Recovery Period

Stroke is the leading cause of disability in adults. Depression after a stroke is detected in one third of patients, complicating physical rehabilitation, worsening functional outcome, increasing mortality rates. The question of the use of antidepressants in the treatment of post-stroke depression is currently not completely resolved, there is no consensus on the most optimal drug. The drugs of choice are selective serotonin reuptake inhibitors, the use of tricyclic antidepressants is possible. A number of clinical studies indicate the effectiveness of selective serotonin reuptake inhibitors in the treatment of post-stroke depression, including through mechanisms including increased neuroplasticity and stimulation of neurogenesis, while others disprove their effectiveness. The article presents a clinical case of the use of vortiroxetin in the patient’s neurorehabilitation in the early recovery period of a stroke, its safety and positive effect are shown.

scholarly journals Selective Serotonin Reuptake Inhibitors for the Prevention of Post-Stroke Depression: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 10 (24) ◽  
pp. 5912
Author(s):  
Daniel Richter ◽  
Jeyanthan Charles James ◽  
Andreas Ebert ◽  
Aristeidis H. Katsanos ◽  
Lisa Mazul-Wach ◽  
...  
Keyword(s):  
Relative Risk ◽  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Absolute Risk ◽  
Serotonin Reuptake Inhibitors ◽  
Selective Serotonin ◽  
Future Research ◽  
Post Stroke ◽  
Stroke Population ◽  
Post Stroke Depression

There are controversial data on the efficacy and safety profile of selective serotonin reuptake inhibitors (SSRIs) to prevent post-stroke depression (PSD). We performed a systematic search in MEDLINE and SCOPUS databases to identify randomized-controlled trials questioning the use of early SSRI therapy in the post-stroke population and its effect on PSD incidence. We included 6 studies with 6560 participants. We extracted the data on PSD occurrence in association with the treatment arm (SSRI versus placebo), as reported by each study. For safety analysis, we extracted the information on adverse events. A random-effects model was used to calculate the pooled relative risk estimates. Early SSRI therapy was associated with a significant reduction of PSD occurrence compared to placebo (10.4% versus 13.8%; relative risk: 0.75 [95% CI, 0.66–0.86]; absolute risk reduction: 3.4%). SSRI therapy increases the risk of bone fracture (RR 2.28 [95% CI, 1.58–3.30]) and nausea (RR 2.05 [95% CI, 1.10–3.82]) in the post-stroke population. Considering the risk-benefit ratio of early SSRI therapy in the post-stroke population, future research should identify high-risk patients for PSD to improve the risk-benefit consideration of this therapy for use in clinical practice.

Abstract T P329: Preadmission Use of Selective Serotonin Reuptake Inhibitors (SSRIs) in Acute Ischemic Stroke

Stroke ◽  
2014 ◽  
Vol 45 (suppl_1) ◽  
Author(s):  
Shawna Cutting ◽  
Laurel Smit ◽  
Renee Jhu ◽  
Bichun Ouyang ◽  
Shyam Prabhakaran
Keyword(s):  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Motor Impairment ◽  
Serotonin Reuptake Inhibitors ◽  
Selective Serotonin ◽  
Stroke Severity ◽  
Discharge Disposition ◽  
And Gender

Objective: To determine if patients admitted with ischemic stroke who were taking selective serotonin reuptake inhibitors (SSRI) at baseline have reduced motor impairment compared to patients not taking an SSRI. Introduction: SSRI use may help patients with motor recovery following ischemic stroke. It is not known whether use of this class of medications prior to stroke leads to decreased stroke severity or motor impairment on admission and improved discharge outcome. Methods: We retrospectively identified all patients admitted to our institution between 2009 and 2012 with first-ever acute ischemic stroke who were taking an SSRI prior to admission (cases). We collected data on patient demographics, clinical stroke severity as measured by the National Institute of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS) score, and disposition at discharge. Controls with acute ischemic stroke who were not taking SSRIs prior to admission were matched 2:1 by age and gender to cases. Results: Eighty cases (mean age 65 +/- 14 years) were identified, of whom 56.2% were female and 63.7% were Caucasian. Median admission NIHSS was 5 (IQR 2-10), and median length of stay (LOS) was 4 days (IQR 3-7). Compared to controls, cases were more likely to have a pre-stroke diagnosis of depression (43.8% vs 7.5%, p=<0.001) or anxiety (13.8% vs 2.5%, p=0.001). Identification of a cardioembolic etiology was more common in cases (41.2% vs 26.6%, p=0.019). Median total NIHSS scores and NIHSS motor component scores on admission (total 5 vs 4, p=0.69; motor 2 vs 1, p=1.0) or at discharge (total 3.5 vs 2, p=0.67; motor 1 vs 0, p=0.76) were not different between cases and controls. Median LOS was similar for controls (5 days, p=0.65). Discharge to home or acute rehab was similar between groups (p=0.85). Conclusions: SSRI use prior to ischemic stroke does not confer a protective effect in reducing initial stroke severity, reducing degree of motor impairment, or improving discharge disposition. Further studies are needed to determine whether there are long-term benefits or other effects.

Sign in / Sign up

Export Citation Format

Share Document